This product is a recombinant human antibody that can recognize IAV HA. This antibody effectively reacting with all influenza A hemagglutinin (HA) subtypes. The antibody is the second cross-group neutralizing antibody for which structures of complexes with both group1 and group 2 HAs have been reported.
Figure 1 MEDI8852 exhibits broad neutralization activity against group l and group ll influenza A viruses with pandemic potential.
MEDI8852 neutralization median inhibitory concentration (IC50) values were determined against a panel of 5 group II influenza viruses and 10 group l influenza A viruses. R347 was used as a control antibody. Solid line depicts the median IC50, and dotted line depict the upper limit of detection, which was 880 ug/mL.
Paules, C. I., Lakdawala, S., McAuliffe, J. M., Paskel, M., Vogel, L., Kallewaard, N. L., ... & Subbarao, K. (2017). The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. The Journal of infectious diseases, 216(3), 356-365.
Figure 2 MEDI8852 decreases respiratory droplet transmission of pH1N1 when administered to naive contact ferrets.
Study design in which 4 ferrets were inoculated intranasally to test the respiratory droplet transmission of pHIN1 to naive contact ferrets given a single dose of MED18852. Nasal washes were colected on the indicated days. Each bar represents the titer of virus from an individual ferret. The x-axis represents days post-experimental infection (infected ferrets) and day after placement in transmission cages labeled as exposure (naive ferrets). The limit of detection is represented as the dashed line and is 10 ⁰˙⁵ TCID₅₀ per mL.
Paules, C. I., Lakdawala, S., McAuliffe, J. M., Paskel, M., Vogel, L., Kallewaard, N. L., ... & Subbarao, K. (2017). The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. The Journal of infectious diseases, 216(3), 356-365.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-078 | Recombinant Anti-IAV HA VHH Single Domain Antibody | FC, CA, IP, FuncS | Llama VHH |
HPAB-0344CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0344CQ) | ELISA, Neut | Llama VHH |
HPAB-0345CQ | Recombinant Llama Anti-IAV HA Single Domain Antibody (HPAB-0345CQ) | ELISA, Neut | Llama VHH |
There are currently no Customer reviews or questions for PABC-393. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABC-393, RRID: AB_3111586)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.